Risk Factors for Severe Disease in Hospitalized Patients With COVID-19 and the Effect
Overview
- Phase
- Not Applicable
- Intervention
- Azvudine
- Conditions
- COVID-19
- Sponsor
- Fifth Affiliated Hospital, Sun Yat-Sen University
- Enrollment
- 4201
- Locations
- 1
- Primary Endpoint
- All-cause mortality of COVID-19 patients
- Status
- Active, not recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
The purpose of this study is to explore the factors that can affect the development of severe cases in hospitalized patients with COVID-19, including basic diseases, laboratory parameters, and clinical manifestations; In addition,to explore whether Azvudine can reduce the mortality of hospitalized patients with COVID-19.
Detailed Description
4201 COVID-19 patients discharged from our hospital were enrolled. Binary logistic regression analysis and ROC curve were used to investigate the role of comorbidities, laboratory parameters and clinical manifestation on progression of COVID-19 patients. We used propensity-score models conditional on baseline characteristics and Univariate Cox regression model to examine whether Azvudine can reduce the mortality of COVID-19 patients.
Investigators
Eligibility Criteria
Inclusion Criteria
- •The COVID-19 positive patients
Exclusion Criteria
- •patients treated with both azvudine and monotamivir;
- •patients receiving other antiviral drugs such as nematavir/ritonavir;
- •age \< 18 years old
Arms & Interventions
Azvudine group
Azvudine group included COVID-19 patients treated with azvudine antiviral therapy;
Intervention: Azvudine
Outcomes
Primary Outcomes
All-cause mortality of COVID-19 patients
Time Frame: Time from onset to death
All-cause mortality of COVID-19 patients